menu
    • menu
    [{"orgOrder":0,"company":"Bioxodes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ir-CPI","moa":"","graph1":"Hematology","graph2":"Phase II","graph3":"Bioxodes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Bioxodes \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Not Applicable"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BIOX-101","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Bioxodes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bioxodes \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Not Applicable"},{"orgOrder":0,"company":"Bioxodes","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Ir-CPI","moa":"FXIa\/XIIa","graph1":"Hematology","graph2":"Phase II","graph3":"Bioxodes","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioxodes \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bioxodes \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Bioxodes

    Menu

    Bioxodes

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bioxodes

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Bioxodes

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ir-CPI

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $15.4 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Bioxodes Secures New Funds to Reach Early 2025 Milestones and Pursue Series B Financing

                            Details : The proceeds will allow the company to deliver full results from BIRCH, its Phase 2a trial of BIOX-101 (Ir-CPI) to treat intracerebral hemorrhage.

                            Product Name : BIOX-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 12, 2025

                            Lead Product(s) : Ir-CPI

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $15.4 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bioxodes

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Bioxodes

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BIOX-101

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bioxodes Meets Enrollment Milestone in Phase 2a Intracerebral Hemorrhagic Stroke Trial

                            Details : BIOX-101 (Ir-CPI) is a FXIa inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with intracerebral hemorrhagic stroke.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 19, 2024

                            Lead Product(s) : BIOX-101

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bioxodes

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed

                            Bioxodes

                            Belgium arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ir-CPI

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bioxodes Meets Enrollment Milestone for BIOX-101 in Intracerebral Hemorrhagic Stroke

                            Details : BIOX-101 (Ir-CPI) is a FXIa inhibitor small molecule drug candidate, which is being evaluated for the treatment of patients with intracerebral hemorrhagic stroke.

                            Product Name : BIOX-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 27, 2024

                            Lead Product(s) : Ir-CPI

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth